Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:26:36 EDT Sat 27 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:ARCT from 2023-04-27 to 2024-04-26 - 26 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-25 16:01U:ARCTNews ReleaseArcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
2024-03-07 16:01U:ARCTNews ReleaseArcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
2024-02-26 09:00U:ARCTNews ReleaseArcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
2024-02-22 08:30U:ARCTNews ReleaseArcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
2024-02-20 09:00U:ARCTNews ReleaseArcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
2024-02-05 08:30U:ARCTNews ReleaseNew COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
2024-02-05 08:30U:ARCTNews ReleaseNew COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
2023-12-21 08:00U:ARCTNews ReleaseCSL and Arcturus Therapeutics ¢ € ™ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
2023-12-21 08:00U:ARCTNews ReleaseCSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
2023-12-04 08:30U:ARCTNews ReleaseArcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-28 08:05U:ARCTNews ReleaseJapan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
2023-11-28 08:00U:ARCTNews ReleaseJapan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics ¢ € ™ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
2023-11-27 08:30U:ARCTNews ReleaseArcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis
2023-11-14 16:01U:ARCTNews ReleaseArcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress
2023-10-25 16:01U:ARCTNews ReleaseArcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023
2023-10-23 16:01U:ARCTNews ReleaseArcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
2023-10-04 08:30U:ARCTNews ReleaseArcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese Government
2023-09-26 08:30U:ARCTNews ReleaseArcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis
2023-09-19 08:30U:ARCTNews ReleaseStudy Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants
2023-09-05 08:30U:ARCTNews ReleaseArcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
2023-08-17 08:30U:ARCTNews ReleaseArcturus Therapeutics to Attend Upcoming Investor Conferences
2023-08-14 09:00U:ARCTNews ReleaseArcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government
2023-08-07 16:01U:ARCTNews ReleaseArcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress
2023-07-24 16:01U:ARCTNews ReleaseArcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023
2023-06-01 08:30U:ARCTNews ReleaseArcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency
2023-05-09 16:01U:ARCTNews ReleaseArcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress